Ask AI
TROP2 Targeted Therapy: Module

CME

TROP-2–Targeted Therapy: Redefining the Therapeutic Landscape in HER2-Negative Breast Cancer

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: February 22, 2024

Expiration: February 21, 2025

Activity

Progress
1
Course Completed

Introduction

In this module, Komal Jhaveri, MD, FACP, provides clinical insights into the current and emerging role of TROP-2‒directed antibody‒drug conjugates (ADCs) in the therapeutic landscape for patients with HER2-negative advanced breast cancer.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

For those providing patient care, how many patients with breast cancer do you provide care for in a typical month?

At this time, what would you recommend as the next best FDA-approved treatment option for this 54-year-old woman?